Department of Medicine 3 – Rheumatology and Immunology

Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial (2018) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution SECUKINUMAB EFFICACY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: META-ANALYSIS OF 4 PHASE 3 TRIALS (2018) Mease P, Kirkham B, Nash P, Balsa A, Combe B, Rech J, Martin R, et al. Conference contribution Update on imaging in gout: contrasting and comparing the role of dual-energy computed tomography to traditional diagnostic and monitoring techniques (2018) Bayat S, Baraf HSB, Rech J Journal article MICRORNA-125B REGULATES APOPTOSIS IN SYSTEMIC SCLEROSIS (2018) Kozlova A, Pachera E, Maurer B, Juengel A, Distler J, Kania G, Distler O Conference contribution RITUXIMAB IN SYSTEMIC SCLEROSIS : SAFETY AND EFFICACY DATA FROM THE EUSTAR NETWORK (2018) Elhai M, Distler O, Smith V, Matucci-Cerinic M, Alegre-Sancho JJ, Truchetet ME, Braun-Moscovici Y, et al. Conference contribution NEW SYSTEMIC SCLEROSIS RISK LOCI IDENTIFIED THROUGH A META-GWAS STRATEGY (2018) Lopez-Isac E, Acosta-Herrera M, Assassi S, Simeon CP, Carreira PE, Castellvi I, Ortego-Centeno N, et al. Conference contribution Racial differences in SSc disease presentation: a European scleroderma trials and research group (EUSTAR) study (2018) Jaeger VK, Siegert E, Hachulla E, Airo P, Valentini G, Matucci-Cerinic M, Scorza R, et al. Conference contribution Orphan Nuclear Receptor Ror alpha Is a Key Regulator of Tgf beta- and WNT-Signaling in Fibrotic Diseases (2018) Kagwiria R, Liang R, Matei AE, Sihler N, Chen CW, Burris T, Distler O, et al. Conference contribution Only a Minor Proportion of Individuals with Anti-Aminoacyl-tRNA Synthetase Autoimmunity Presents with the Clinical Picture of "Antisynthetase-Syndrome" (2018) Knitza J, Schenker H, Schett G, Distler J Conference contribution Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease (2018) Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Koetter I, Hachulla E, et al. Journal article